US Stock MarketDetailed Quotes
IONS Ionis Pharmaceuticals
- 35.410
- -0.050-0.14%
Trading Nov 26 13:22 ET
5.59BMarket Cap-14512P/E (TTM)
36.005High35.030Low430.25KVolume35.490Open35.460Pre Close15.23MTurnover0.28%Turnover RatioLossP/E (Static)157.90MShares54.44552wk High8.44P/B5.55BFloat Cap33.33052wk Low--Dividend TTM156.65MShs Float86.582Historical High--Div YieldTTM2.75%Amplitude2.500Historical Low35.395Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Ionis Pharmaceuticals Stock Forum
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
$Arcutis Biotherapeutics (ARQT.US)$ :
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$
BIGGEST MOVERS FROM THIS WEEK
The CEO of $CNS Pharmaceuticals (CNSP.US)$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.
$Dermata Therapeutics (DRMA.US)$ received FDA approval for its proposed protocols and regulations for the Phase 3 clin...
In reaction to earnings/guidance:
• $CalAmp (CAMP.US)$ +0.6%
Other news:
• $Cano Health (CANO.US)$ +6.1% ( $Humana (HUM.US)$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics (CORT.US)$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial (LPLA.US)$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona (XRAY.US)$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +2.9% (tr...
No comment yet